Atlas Trials

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Clinical trial NCT06924970 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06924970
Sponsor
Agios Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell Disease
Start date
2025-05-01
Primary completion
2026-05-01
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.